AstraZeneca to discontinue Epanova trial, expects $100 mln writedown

(Reuters) - AstraZeneca said on Monday it will discontinue a late-stage trial for heart disease drug Epanova to treat patients with mixed dyslipidaemia and expects a $100 million writedown to hit its core profit in the fourth quarter.The biggest British drugmaker by market value said the decision, which followed recommendations from an independent data monitoring committee, was due to low likelihood of Epanova's benefit to patients with mixed dyslipidaemia. "We are disappointed by these..